Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
Adults with relapsed or refractory B-cell acute lymphoblastic leukemia have a dismal prognosis with a short median overall survival that can be measured in months. Because most patients will have chemotherapy-resistant disease, allogeneic hematopoietic stem cell transplantation remains the only pote...
Main Authors: | Lee, Kum Ja, Chow, Vivian, Weissman, Ashley, Tulpule, Sunil, Aldoss, Ibrahim, Akhtari, Mojtaba |
---|---|
Format: | Online |
Language: | English |
Published: |
Dove Medical Press
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003562/ |
Similar Items
-
Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab
by: Hladnik,1, Lindsay, et al.
Published: (2016) -
Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
by: Portell, Craig A, et al.
Published: (2013) -
Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
by: Le Jeune, Caroline, et al.
Published: (2016) -
Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
by: Ribera, Josep-Maria, et al.
Published: (2015) -
Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab
by: Litzow, Mark R
Published: (2014)